Calton & Associates’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Calton & Associates’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-125	Closed	–	–	1489
2017 Q4	$0	Buy	+125	New	+$215	﹤0.01%	1542

Other funds holding ANTH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Calton & Associates's ANTH Position: Q1 2018 in Review

Calton & Associates sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q1 2018, closing a stake of 125 shares.

Calton & Associates first reported a position in ANTH in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 28 funds tracked by Wall St. Rank hold ANTH as of Q1 2018.

Calton & Associates reported no remaining Anthera Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 125 Anthera Pharmaceuticals, Inc. shares in Q1 2018.
Calton & Associates first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
Calton & Associates's Anthera Pharmaceuticals, Inc. position peaked at $0 in Q4 2017.
28 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.